Skip to main content

Table 3 Characteristics and clinical data of 721 NSCLC and 150 SCLC patients of CAPUA study

From: Genetic polymorphisms in MMP 2, 9 and 3genes modify lung cancer risk and survival

Variables NSCLC SCLC
  Patients Deaths MST
(months)
Log-rank HR 95% CI Patients Deaths MST
(months)
Log-rank HR 95% CI
  n %       n %      
Gender      0.293        0.053   
Male 643 89.2 598 9.3   1.00   134 89.3 123 8.3   1.00  
Female 78 10.8 68 12.5   0.87 0.68-1.12 16 10.7 14 14.5   0.57 0.32-1.02
Age (years)      0.083        0.041   
≤ 68 375 52.0 342 11.3   1.00   79 52.7 69 9.8   1.00  
> 68 346 48.0 324 8.2   1.15 0.98-1.34 71 47.3 68 7.6   1.42 1.01-2.00
Smoking Status      0.585        0.025   
Never 45 6.3 41 10.5   1.00   7 4.7 6 54.2   1.00  
Ever 672 93.7 621 9.5   0.92 0.67-1.26 142 95.3 130 8.4   2.51 1.09-5.75
Former 307 45.8 284 9.4 0.809 0.90 0.65-1.25 59 41.8 54 7.5 0.022 2.88 1.29-6.43
Current 363 54.2 335 9.5   0.93 0.67-1.28 82 58.2 75 9.2   2.24 1.02-4.91
Histological Types      0.608          
Squamous cell carcinoma 358 49.6 335 10.9   1.00         
Adenocarcinoma 264 36.6 240 10.2   1.05 0.89-1.24        
Others 99 13.7 91 7.8   1.12 0.89-1.43        
Clinical stages      0.000          
I 186 26.1 151 26.1   1.00       0.000   
II 58 8.1 51 19.7   1.45 1.05-2.00        
III 244 34.3 238 9.6   2.26 1.83-2.79        
IV 224 31.5 220 5.2   3.97 3.19-4.94        
Limited stage (LS)         78 52.3 69 12.2   1.00  
Extend stage (ES)         71 47.7 67 5.8   2.19 1.54-3.11
Surgical Operation      0.000          
None 523 72.5 509 7.2   1.00         
Yes 198 27.5 157 30.9   0.32 0.27-0.39        
Chemo or Radiotherapy      0.469          
None 301 41.7 262 6.9   1.00         
Yes 420 58.3 412 11.7   1.06 0.90-1.24        
Chemotherapy             0.000   
None         29 19.3 28 1.6   1.00  
Yes         121 80.7 109 9.9   0.41 0.26-0.62
Radiotherapy             0.000   
None         74 49.3 71 5.4   1.00  
Yes         76 50.7 66 12.1   0.46 0.32-0.64
  1. NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; MST: median survival